The case was voluntarily dismissed after the court noted the default
SGLT2i, sodium-glucose cotransporter 2 inhibitor
Expected outcomes based on trial data: Average weight loss of 24.2% at 48 weeks (phase 2) Average weight loss of 28.7% at 68 weeks (phase 3, TRIUMPH-4) 100% of participants achieved 5% or greater weight loss 93% achieved 10% or greater 83% achieved 15% or greater Moderate weight loss protocol (8mg target) For researchers who want significant weight loss but have a lower tolerance for side effects, stopping the escalation at 8mg is a validated approach
Weight loss results vary depending on factors such as: For many users, progress tends to happen steadily over time rather than rapidly
We do know that GLP-1s have powerful anti-inflammatory effects, but we dont yet fully understand: Long-term impact on Lipedema fat Effect on fibrosis Impact on lymphatic health Interaction with Lipedema-specific metabolic patterns For now, the approach must be personalised, cautious, and monitored
21+ only
